$16.06 Million in Sales Expected for Conatus Pharmaceuticals Inc. (CNAT) This Quarter

Equities analysts expect that Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) will post $16.06 million in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Conatus Pharmaceuticals’ earnings, with estimates ranging from $10.80 million to $19.25 million. The company is expected to issue its next earnings report on Tuesday, November 14th.

According to Zacks, analysts expect that Conatus Pharmaceuticals will report full year sales of $16.06 million for the current year, with estimates ranging from $38.80 million to $54.16 million. For the next year, analysts forecast that the firm will report sales of $74.20 million per share, with estimates ranging from $32.75 million to $117.80 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Conatus Pharmaceuticals.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). The company had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $9.33 million. During the same period last year, the firm earned ($0.30) earnings per share.

CNAT has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Conatus Pharmaceuticals in a report on Thursday, June 29th. Zacks Investment Research downgraded Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Stifel Nicolaus reaffirmed a “buy” rating and set a $10.00 target price on shares of Conatus Pharmaceuticals in a report on Thursday, August 3rd. Finally, Seaport Global Securities reaffirmed a “buy” rating and set a $16.00 target price on shares of Conatus Pharmaceuticals in a report on Friday, October 6th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $16.17.

TRADEMARK VIOLATION WARNING: “$16.06 Million in Sales Expected for Conatus Pharmaceuticals Inc. (CNAT) This Quarter” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://ledgergazette.com/2017/10/14/16-06-million-in-sales-expected-for-conatus-pharmaceuticals-inc-cnat-this-quarter.html.

Institutional investors have recently made changes to their positions in the stock. Voya Investment Management LLC purchased a new stake in Conatus Pharmaceuticals in the 2nd quarter worth about $101,000. Bank of Montreal Can purchased a new stake in Conatus Pharmaceuticals in the 2nd quarter worth about $109,000. FNY Partners Fund LP lifted its stake in Conatus Pharmaceuticals by 98.0% in the 2nd quarter. FNY Partners Fund LP now owns 19,800 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 9,800 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in Conatus Pharmaceuticals in the 2nd quarter worth about $115,000. Finally, Strs Ohio purchased a new stake in Conatus Pharmaceuticals in the 2nd quarter worth about $153,000. 33.13% of the stock is owned by hedge funds and other institutional investors.

Shares of Conatus Pharmaceuticals (CNAT) traded down 2.95% on Wednesday, reaching $5.27. 247,414 shares of the company traded hands. The company’s market capitalization is $158.12 million. Conatus Pharmaceuticals has a 52-week low of $1.45 and a 52-week high of $9.40. The firm has a 50-day moving average of $5.59 and a 200-day moving average of $5.85.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Get a free copy of the Zacks research report on Conatus Pharmaceuticals (CNAT)

According to Zacks, analysts expect that Conatus Pharmaceuticals will report full year sales of $16.06 million for the current year, with estimates ranging from $38.80 million to $54.16 million. For the next year, analysts forecast that the firm will report sales of $74.20 million per share, with estimates ranging from $32.75 million to $117.80 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Conatus Pharmaceuticals.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). The company had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $9.33 million. During the same period last year, the firm earned ($0.30) earnings per share.

CNAT has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Conatus Pharmaceuticals in a report on Thursday, June 29th. Zacks Investment Research downgraded Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Stifel Nicolaus reaffirmed a “buy” rating and set a $10.00 target price on shares of Conatus Pharmaceuticals in a report on Thursday, August 3rd. Finally, Seaport Global Securities reaffirmed a “buy” rating and set a $16.00 target price on shares of Conatus Pharmaceuticals in a report on Friday, October 6th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $16.17.

TRADEMARK VIOLATION WARNING: “$16.06 Million in Sales Expected for Conatus Pharmaceuticals Inc. (CNAT) This Quarter” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://ledgergazette.com/2017/10/14/16-06-million-in-sales-expected-for-conatus-pharmaceuticals-inc-cnat-this-quarter.html.

Institutional investors have recently made changes to their positions in the stock. Voya Investment Management LLC purchased a new stake in Conatus Pharmaceuticals in the 2nd quarter worth about $101,000. Bank of Montreal Can purchased a new stake in Conatus Pharmaceuticals in the 2nd quarter worth about $109,000. FNY Partners Fund LP lifted its stake in Conatus Pharmaceuticals by 98.0% in the 2nd quarter. FNY Partners Fund LP now owns 19,800 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 9,800 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in Conatus Pharmaceuticals in the 2nd quarter worth about $115,000. Finally, Strs Ohio purchased a new stake in Conatus Pharmaceuticals in the 2nd quarter worth about $153,000. 33.13% of the stock is owned by hedge funds and other institutional investors.

Shares of Conatus Pharmaceuticals (CNAT) traded down 2.95% on Wednesday, reaching $5.27. 247,414 shares of the company traded hands. The company’s market capitalization is $158.12 million. Conatus Pharmaceuticals has a 52-week low of $1.45 and a 52-week high of $9.40. The firm has a 50-day moving average of $5.59 and a 200-day moving average of $5.85.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Get a free copy of the Zacks research report on Conatus Pharmaceuticals (CNAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.